Jazz Pharmaceuticals (JAZZ) Q1 Earnings and Revenues Lag Estimates
Jazz (JAZZ) delivered earnings and revenue surprises of -62.75% and 8.52%, respectively, for the quarter ended March 2025. Do the…
87,020€
-0,62%
Echtzeit-Aktienkurs Jazz Pharmaceuticals PLC
Bid:
Ask:
Nachrichten zur Jazz Pharmaceuticals PLC Aktie
Jazz Pharmaceuticals (JAZZ) Earnings Expected to Grow: Should You Buy?
Jazz (JAZZ) doesnt possess the right combination of the two key ingredients for a likely earnings beat in its upcoming…
Akari Therapeutics Appoints Biotechnology Industry Leader, Abizer Gaslightwala, as President and Chief Executive Officer
Former SVP and Franchise Head for US Oncology at Jazz Pharmaceuticals, with established track record for leading a portfolio of…
Jazz Pharmaceuticals and Boston Beer Company have been highlighted as Zacks Bull and Bear of the Day
Jazz Pharmaceuticals and Boston Beer Company are part of the Zacks Bull and Bear of the Day article.…
Jazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio
-Dordaviprone addresses a significant unmet patient need for patients with rare, high-grade brain tumors-…
Zacks.com featured highlights include EverQuote, Jazz Pharmaceuticals, The Progressive, Sony and NatWest
EverQuote, Jazz Pharmaceuticals, The Progressive, Sony and NatWest have been highlighted in this Screen of The Week article.…
Jazz Pharmaceuticals (JAZZ) is a Top-Ranked Growth Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.…
Jazz Pharmaceuticals: 60 % Kurspotenzial durch Rekordumsatz und gewonnenes Patentduell
Die Aktie von Jazz bleibt weiterhin hochinteressant. Im November 2024 berichtete ich sowohl an dieser Stelle als auch anschließend in…
Why Jazz Pharmaceuticals (JAZZ) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Heres why…
Jazz Pharmaceuticals plc 2024 Q4 - Results - Earnings Call Presentation
…
Jazz Pharmaceuticals (JAZZ) Tops Q4 Earnings and Revenue Estimates
Jazz (JAZZ) delivered earnings and revenue surprises of 13.99% and 2.57%, respectively, for the quarter ended December 2024. Do the…
ALX Oncology Announces New Data Demonstrating Evorpacept in Combination with Zanidatamab Generates Promising Antitumor Activity in Advanced Breast Cancer
SOUTH SAN FRANCISCO, Calif., Dec. 10, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology” or “the…
Jazz Pharmaceuticals: Kurspotenzial von 50 % durch neue Therapie von aggressivem Lungenkrebs
Die Innovationskraft von Unternehmen im Megatrend Biopharmazeutika bringt seit Monaten attraktive Anlageoptionen hervor. Mit dem Potenzial, komplexe Krankheiten wie Krebs…
Jazz Pharmaceuticals plc (JAZZ) Q3 2024 Earnings Call Transcript
…
Global Oral Transmucosal Drugs Market Size To Exceed USD 62.3 Billion By 2033 | CAGR Of 6.5%
The Global Oral Transmucosal Drugs Market Size was Valued at USD 33.2 Billion in 2023 and the Worldwide Oral Transmucosal…
Jazz Pharmaceuticals plc 2024 Q1 - Results - Earnings Call Presentation
…
Biotech-Einhorn! FDA Zulassung für das CBD-Wunder?!
Anzeige / WerbungEin einziges Medikament, das auf CBD basiert ist bislang von der FDA zur Verwendung zugelassen worden. Resultat: Der…
Earnings call: Jazz Pharmaceuticals reports robust 2023 financials By Investing.com
Earnings call: Jazz Pharmaceuticals reports robust 2023 financials…
Jazz Pharmaceuticals PLC (JAZZ) Q4 2023 Earnings Call Transcript
…
Jazz Pharmaceuticals plc 2023 Q4 - Results - Earnings Call Presentation
…